RFG Advisory LLC Decreases Holdings in The Clorox Company (NYSE:CLX)

RFG Advisory LLC trimmed its holdings in shares of The Clorox Company (NYSE:CLX) by 3.5% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 2,832 shares of the company’s stock after selling 103 shares during the period. RFG Advisory LLC’s holdings in Clorox were worth $404,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors also recently bought and sold shares of the business. Norges Bank purchased a new stake in shares of Clorox in the 4th quarter valued at about $101,609,000. Imprint Wealth LLC lifted its holdings in shares of Clorox by 16,986.8% in the 2nd quarter. Imprint Wealth LLC now owns 551,392 shares of the company’s stock valued at $55,139,000 after purchasing an additional 548,165 shares during the last quarter. Qube Research & Technologies Ltd lifted its holdings in shares of Clorox by 75.9% in the 3rd quarter. Qube Research & Technologies Ltd now owns 1,130,481 shares of the company’s stock valued at $148,161,000 after purchasing an additional 487,974 shares during the last quarter. International Assets Investment Management LLC lifted its holdings in shares of Clorox by 17,658.5% in the 4th quarter. International Assets Investment Management LLC now owns 484,453 shares of the company’s stock valued at $69,078,000 after purchasing an additional 481,725 shares during the last quarter. Finally, Acadian Asset Management LLC increased its position in Clorox by 39.6% in the 3rd quarter. Acadian Asset Management LLC now owns 1,467,713 shares of the company’s stock valued at $192,319,000 after acquiring an additional 415,999 shares during the period. 78.53% of the stock is owned by hedge funds and other institutional investors.

Clorox Price Performance

Shares of NYSE:CLX opened at $141.98 on Friday. The business’s 50 day simple moving average is $151.19 and its 200-day simple moving average is $141.36. The firm has a market capitalization of $17.62 billion, a price-to-earnings ratio of 225.37, a price-to-earnings-growth ratio of 2.25 and a beta of 0.43. The company has a debt-to-equity ratio of 11.37, a current ratio of 0.89 and a quick ratio of 0.57. The Clorox Company has a 12 month low of $114.68 and a 12 month high of $178.21.

Clorox (NYSE:CLX) last posted its earnings results on Thursday, February 1st. The company reported $2.16 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.08 by $1.08. Clorox had a return on equity of 319.41% and a net margin of 1.09%. The firm had revenue of $1.99 billion for the quarter, compared to analyst estimates of $1.80 billion. During the same quarter in the prior year, the company earned $0.98 EPS. Clorox’s revenue was up 16.0% on a year-over-year basis. As a group, equities analysts forecast that The Clorox Company will post 5.52 earnings per share for the current fiscal year.

Clorox Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, May 10th. Investors of record on Wednesday, April 24th will be paid a $1.20 dividend. This represents a $4.80 dividend on an annualized basis and a yield of 3.38%. The ex-dividend date is Tuesday, April 23rd. Clorox’s payout ratio is currently 761.92%.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on CLX. Bank of America upgraded Clorox from an “underperform” rating to a “neutral” rating and boosted their price target for the company from $120.00 to $150.00 in a research report on Friday, December 15th. Citigroup restated a “neutral” rating and issued a $165.00 price target (down previously from $170.00) on shares of Clorox in a research report on Tuesday, April 2nd. The Goldman Sachs Group began coverage on Clorox in a research report on Friday, March 1st. They issued a “sell” rating and a $140.00 price target on the stock. JPMorgan Chase & Co. boosted their price target on Clorox from $145.00 to $152.00 and gave the company a “neutral” rating in a research report on Thursday, January 18th. Finally, Barclays dropped their target price on Clorox from $148.00 to $136.00 and set an “underweight” rating on the stock in a research report on Wednesday. Four research analysts have rated the stock with a sell rating and twelve have issued a hold rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $149.13.

About Clorox

The Clorox Company manufactures and markets consumer and professional products worldwide. It operates through four segments: Health and Wellness, Household, Lifestyle, and International. The Health and Wellness segment offers cleaning products, such as laundry additives and home care products primarily under the Clorox, Clorox2, Scentiva, Pine-Sol, Liquid-Plumr, Tilex, and Formula 409 brands; professional cleaning and disinfecting products under the CloroxPro and Clorox Healthcare brands; professional food service products under the Hidden Valley brand; and vitamins, minerals and supplement products under the RenewLife, Natural Vitality, NeoCell, and Rainbow Light brands in the United States.